import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'egypt-vaccines-market-report';

/**
 * Curated copy for the Egypt vaccines programmatic report.
 * SEO target query: "egypt vaccine market" — title/H1 use exact phrase; URL slug unchanged.
 * Market sizing: BioNixus market analysis, 2026 (~USD 198M → ~USD 348M 2030, ~17.4% CAGR).
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const EGYPT_VACCINES_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'Egypt Vaccine Market Report 2026',
  metaTitle: 'Egypt Vaccine Market 2026 | Size & UHI | BioNixus',
  metaDescription:
    'Egypt vaccine market ~USD 198M in 2026 (BioNixus analysis), ~17.4% CAGR: UHI childhood immunization, HPV school programmes, EDA registration—MENA decision-ready intelligence.',
  modifiedDate: '2026-08-14',
  heroLead:
    'The Egypt vaccine market is shaped by Universal Health Insurance expansion of childhood immunization, EDA registration and pricing controls, and school-based HPV and adult-immunisation programmes that vary sharply between Cairo’s private corridors and rural Upper Egypt.',
  summaryPara1:
    'BioNixus sizes the Egypt vaccine market at roughly USD 198 million in 2026, advancing toward about USD 348 million by 2030 at roughly 17.4% CAGR. UHI-expanded childhood immunization anchors government volume; HPV gender-neutral school programmes and adult influenza/pneumococcal growth add upside, while Cairo international schools and private clinics accelerate optional uptake. EDA governs registration and pricing; local manufacturing capacity influences supply security. Sizing reflects BioNixus market analysis, 2026.',
  summaryPara2:
    'Use this report with the [Egypt healthcare market report](/egypt-healthcare-market-report) for macro context, the [GCC vaccines market report](/market-reports/gcc-vaccines-market-report) for a Gulf comparator, the [Saudi Arabia vaccine market report](/market-reports/saudi-arabia-vaccines-market-report) for BioNixus’s flagship Middle East vaccine briefing, [vaccines research](/healthcare-market-research/therapy/vaccines) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork. BioNixus vaccine trackers sit alongside biologics, biosimilars, oncology, and rare-disease insight programmes.',
  marketAccessNotes:
    'UHI expanded childhood immunization driving government schedule volume; EDA registration and price controls gating launch economics; HPV school programmes with rural cultural gatekeepers; Cairo private and international-school rapid uptake; local manufacturing and cold-chain capacity shaping supply security',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat Egypt vaccines as a dual public–private market. UHI schedule inclusion and EDA pricing set the government floor; private clinics and international schools create a premium optional channel. We pair public-health and school-programme stakeholder interviews with private-provider and payer depth, and we map Upper Egypt cultural and logistics friction that forecasts often miss. Cairo corridor clinics can adopt HPV and adult vaccines faster than rural governorates where cold-chain distance and community gatekeepers slow school campaigns — BioNixus sizes those gaps explicitly rather than applying Cairo uptake curves nationally.',
  commercialOutlookParagraph:
    'The outlook to 2030 is strong-growth and policy-sensitive. Childhood base expands with UHI coverage; upside comes from HPV school programmes and adult immunisation. Manufacturers should stress-test volume against EDA pricing, UHI formulary timing, and rural–urban uptake gaps before locking Egypt revenue targets. Scenario planning should separate government schedule volume, school-mandate execution years, and private optional uptake because each channel follows different evidence and budget gates under Egypt’s Universal Health Insurance rollout.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with desk review of UHI, EDA, and ministry immunisation guidance, plus primary modules where data is available. Outputs support market access and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the Egypt vaccine market in 2026?',
      answer:
        'BioNixus sizes the Egypt vaccine market at roughly USD 198 million in 2026, advancing toward about USD 348 million by 2030 at roughly 17.4% CAGR. Government UHI childhood immunization anchors volume; HPV school programmes and adult influenza/pneumococcal growth, plus Cairo private uptake, drive expansion. Use the Egypt healthcare market report for macro sizing and the Saudi Arabia vaccine market report for a Gulf policy comparator.',
    },
    {
      question: 'How does UHI shape vaccine access in Egypt?',
      answer:
        'Universal Health Insurance expansion determines which schedule vaccines are funded and delivered for enrolled populations. Listing and programme inclusion decisions matter as much as EDA registration for government volume. BioNixus maps UHI programme timing alongside private-channel demand so teams do not treat Egypt as a single uniform channel.',
    },
    {
      question: 'How does BioNixus help vaccine teams in Egypt?',
      answer:
        'BioNixus designs bilingual Egypt vaccines programmes: public-health and school-programme interviews, EDA and UHI access mapping, private-clinic demand sizing, and KOL mapping tied to real immunisation influence. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
    {
      question: 'What vaccines drive Egypt market growth to 2030?',
      answer:
        'HPV school programmes, adult pneumococcal and influenza expansion, and continued UHI childhood schedule coverage are the primary growth corridors BioNixus tracks for Egypt through 2030. Optional private-channel vaccines in Cairo and Alexandria add premium upside but do not replace government schedule volume in national forecasts. Pair this briefing with the GCC vaccines report when comparing Gulf pilgrimage-driven demand with Egypt UHI expansion dynamics.',
    },
  ],
};
